# Biotech Daily Digest — 2025-11-13

**43 items from 4 sources**

## Summary by Source

- Endpoints News: 7 items
- Fierce Biotech: 11 items
- Regeneron Press Releases: 1 item
- arXiv q-bio: 24 items


## Endpoints News

- **[Merck KGaA still in tariff talks with the White House, weeks after deal was announced](https://endpoints.news/merck-kgaa-still-in-tariff-talks-with-the-white-house-weeks-after-deal-was-announced/)**  
  _Thu, 13 Nov 2025 14:29:36 +0000_  
  Merck KGaA is still in negotiations with the White House to determine how much its drug products will be exempt from President Donald Trump’s upcoming pharmaceutical tariffs, CFO Helene von Roeder said.

 "It's a little ...

- **[Zealand pauses development of GLP-1/GLP-2 obesity candidate](https://endpoints.news/zealand-pauses-development-of-glp-1-glp-2-obesity-candidate/)**  
  _Thu, 13 Nov 2025 11:50:28 +0000_  
  Zealand Pharma said Thursday it has paused one of its assets for obesity. The GLP-1/GLP-2 dual agonist dapiglutide had completed an investigator-led Phase 2 trial and was slated to begin another under Zealand’s direction.  ...

- **[Novartis says Phase 3 data prove new antimalarial could address resistance](https://endpoints.news/novartis-says-phase-3-data-prove-new-antimalarial-could-address-resistance/)**  
  _Wed, 12 Nov 2025 22:00:50 +0000_  
  Novartis’ experimental malaria treatment passed a Phase 3 trial, bringing it one step closer to becoming the newest tool in an aging arsenal of antimalarials.

 The drug, called GanLum, was non-inferior to Novartis’ standard-of-care treatment ...

- **[Lilly drops CVS as drug benefits manager — report](https://endpoints.news/lilly-drops-cvs-as-drug-benefits-manager-report/)**  
  _Wed, 12 Nov 2025 20:08:40 +0000_  
  Eli Lilly has dropped CVS Health as its pharmacy benefit manager, selecting Rightway instead, according to a report from Bloomberg News.

 The outlet reported that at the beginning of the new ...

- **[Chinese biotechs are shedding their fast-follower reputations as innovation surges](https://endpoints.news/chinese-biotechs-are-shedding-their-fast-follower-reputations-as-innovation-surges/)**  
  _Wed, 12 Nov 2025 18:18:10 +0000_  
  LONDON — China’s biotech sector is steadily moving beyond a “me-too” approach to drug development thanks to a surge in quality talent, regulatory flexibility and a level of speed that’s tough to rival, industry executives said ...

- **[Immatics shares early bispecific data as it seeks to make its name beyond cell therapy](https://endpoints.news/immatics-shares-early-bispecific-data-as-it-seeks-to-make-its-name-beyond-cell-therapy/)**  
  _Wed, 12 Nov 2025 16:42:44 +0000_  
  Immatics is planning to advance two T cell receptor-based bispecific antibodies based on results reported Wednesday across Phase 1 trials.

 The company’s bispecific work previously faced questions when Bristol Myers Squibb ...

- **[Alkermes reports messy Phase 2 narcolepsy data, stock drops](https://endpoints.news/alkermes-reports-messy-phase-2-narcolepsy-data-stock-drops/)**  
  _Wed, 12 Nov 2025 15:59:00 +0000_  
  Alkermes’ quest to develop a new narcolepsy drug became murkier on Wednesday following another Phase 2 readout.

 The company claimed success, noting the 18 mg high dose achieved a statistically significant ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/medtech/grails-third-quarter-sales-jump-medtech-eyes-q1-fda-galleri-pma-submission" hreflang="en">Grail sees Q3 sales jump, eyes Q1 for FDA Galleri PMA submission</a>](https://www.fiercebiotech.com/medtech/grails-third-quarter-sales-jump-medtech-eyes-q1-fda-galleri-pma-submission)**  
  _Nov 13, 2025 3:57am_  
  Grail saw a sharp rise in third-quarter sales as it outlined a firmer FDA submission date for its Galleri cancer blood test.

- **[<a href="https://www.fiercebiotech.com/biotech/korro-lays-34-staff-lead-drug-disappoints-and-novo-nordisk-pauses-pact" hreflang="en">Korro lays off 34% of staff as lead drug disappoints and Novo Nordisk pauses pact</a>](https://www.fiercebiotech.com/biotech/korro-lays-34-staff-lead-drug-disappoints-and-novo-nordisk-pauses-pact)**  
  _Nov 13, 2025 5:07am_  
  Korro Bio delivered a double whammy of bad news, reporting lackluster data on its lead candidate and a pause to its partnership with Novo Nordisk. The biotech, which suffered a 79% stock drop in the wake of the updates, is laying off 34% of its employees to extend its cash runway deeper into 2027.

- **[<a href="https://www.fiercebiotech.com/biotech/novartis-resistance-busting-malaria-drug-ganlum-hits-phase-3-goal" hreflang="en">Novartis' resistance-busting malaria drug GanLum hits phase 3 goal</a>](https://www.fiercebiotech.com/biotech/novartis-resistance-busting-malaria-drug-ganlum-hits-phase-3-goal)**  
  _Nov 13, 2025 3:58am_  
  A phase 3 trial of Novartis’ next-generation malaria treatment has met its primary endpoint, positioning the drugmaker to seek approval of a therapy with the potential to kill drug-resistant parasites.

- **[<a href="https://www.fiercebiotech.com/medtech/promega-msi-tech-wins-fda-approval-companion-diagnostic-keytruda-lenvima-combo-uterine" hreflang="en">Promega wins FDA approval as companion diagnostic for Keytruda-Lenvima combo in uterine cancer</a>](https://www.fiercebiotech.com/medtech/promega-msi-tech-wins-fda-approval-companion-diagnostic-keytruda-lenvima-combo-uterine)**  
  _Nov 13, 2025 2:56am_  
  Promega has scored an FDA green light for its microsatellite instability testing technology as a companion diagnostic for Merck and Eisai’s Keytruda-Lenvima combination for patients with advanced endometrial carcinoma.

- **[<a href="https://www.fiercebiotech.com/biotech/genetic-medicine-outfit-nchroma-sheds-staff-research-reorganization" hreflang="en">Genetic medicine outfit nChroma sheds staff in research reorg</a>](https://www.fiercebiotech.com/biotech/genetic-medicine-outfit-nchroma-sheds-staff-research-reorganization)**  
  _Nov 12, 2025 5:13pm_  
  After forming from a merger hashed out over plates of tacos about a year ago, nChroma Bio is laying off staff and deprioritizing the research spearheaded by one of its founding companies.

- **[<a href="https://www.fiercebiotech.com/biotech/fdas-new-plausible-mechanism-pathway-accelerate-bespoke-gene-editing-therapies" hreflang="en">Vinay Prasad, Martin Makary unveil new FDA path for accelerating custom gene editing therapies</a>](https://www.fiercebiotech.com/biotech/fdas-new-plausible-mechanism-pathway-accelerate-bespoke-gene-editing-therapies)**  
  _Nov 12, 2025 3:52pm_  
  In a highly anticipated article, FDA officials Vinay Prasad, M.D., and Martin Makary, M.D., outlined a novel regulatory pathway that could trigger a seismic shift in how bespoke gene editing therapies are developed and approved.

- **[<a href="https://www.fiercebiotech.com/biotech/abbvie-cuts-ties-calico-100-scientists-after-11-year-partnership" hreflang="en">AbbVie to end Calico collab after 11-year run, plans layoffs: Stat</a>](https://www.fiercebiotech.com/biotech/abbvie-cuts-ties-calico-100-scientists-after-11-year-partnership)**  
  _Nov 12, 2025 12:51pm_  
  AbbVie is ending an 11-year agreement with Alphabet’s Calico Labs, according to an internal email obtained by Stat.

- **[<a href="https://www.fiercebiotech.com/cro/bms-boosts-cancer-trials-sarah-cannons-clinical-research-platform" hreflang="en">BMS boosts cancer trials with Sarah Cannon’s clinical research platform</a>](https://www.fiercebiotech.com/cro/bms-boosts-cancer-trials-sarah-cannons-clinical-research-platform)**  
  _Nov 12, 2025 11:45am_  
  Bristol Myers Squibb is expanding a partnership with oncology organization Sarah Cannon Research Institute, tapping into SCRI’s community-based clinical trial network.

- **[<a href="https://www.fiercebiotech.com/pharma/jj-legend-withdraw-ash-abstract-assessing-carvykti-against-gilead-arcellxs-rival-car-t" hreflang="en">UPDATED: J&amp;J, Legend withdraw ASH abstract assessing Carvykti against Gilead, Arcellx's rival CAR-T</a>](https://www.fiercebiotech.com/pharma/jj-legend-withdraw-ash-abstract-assessing-carvykti-against-gilead-arcellxs-rival-car-t)**  
  _Nov 12, 2025 11:16am_  
  “At this point, the abstract was withdrawn in alignment with the authors, and we are looking forward to future opportunities to share the data,” Legend’s president of Carvykti, Alan Bash, said Wednesday.

- **[<a href="https://www.fiercebiotech.com/biotech/leap-therapeutics-jumps-bio-crypto-after-winding-down-cancer-program" hreflang="en">Leap Therapeutics jumps from bio to crypto after winding down cancer program</a>](https://www.fiercebiotech.com/biotech/leap-therapeutics-jumps-bio-crypto-after-winding-down-cancer-program)**  
  _Nov 12, 2025 10:13am_  
  Who would have predicted that one of the hottest trends for beleaguered biotechs in 2025 would be to rebrand as a crypto company?

- **[<a href="https://www.fiercebiotech.com/biotech/alkermes-races-phase-3-after-posting-another-narcolepsy-win" hreflang="en">Alkermes races to phase 3 after posting another narcolepsy win</a>](https://www.fiercebiotech.com/biotech/alkermes-races-phase-3-after-posting-another-narcolepsy-win)**  
  _Nov 12, 2025 9:30am_  
  Alkermes has reported another phase 2 win for its narcolepsy drug candidate, succeeding where Takeda failed to maintain its hopes of being first to market in the indication.


## Regeneron Press Releases

- **[Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs](https://investor.regeneron.com/news-releases/news-release-details/regeneron-highlights-progress-american-society-hematology-ash)**  
  _Thu, 13 Nov 2025 07:00:00 -0500_  
  Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a BCMAxCD3 bispecific antibody as a monotherapy in this setting Additional oral presentation spotlights data for odronextamab in combination with chemotherapy,


## arXiv q-bio

- **[Compact Artificial Neural Network Models for Predicting Protein Residue - RNA Base Binding](https://arxiv.org/abs/2511.08648)**  
  _Thu, 13 Nov 2025 00:00:00 -0500_  
  arXiv:2511.08648v1 Announce Type: new 
Abstract: Large Artificial Neural Network (ANN) models have demonstrated success in various domains, including general text and image generation, drug discovery, and protein-RNA (ribonucleic acid) binding tasks. However, these models typically demand substantial computational res…

- **[Bio AI Agent: A Multi-Agent Artificial Intelligence System for Autonomous CAR-T Cell Therapy Development with Integrated Target Discovery, Toxicity Prediction, and Rational Molecular Design](https://arxiv.org/abs/2511.08649)**  
  _Thu, 13 Nov 2025 00:00:00 -0500_  
  arXiv:2511.08649v1 Announce Type: new 
Abstract: Chimeric antigen receptor T-cell (CAR-T) therapy represents a paradigm shift in cancer treatment, yet development timelines of 8-12 years and clinical attrition rates exceeding 40-60% highlight critical inefficiencies in target selection, safety assessment, and molecula…

- **[Data-driven spatiotemporal modeling reveals personalized trajectories of cortical atrophy in Alzheimer's disease](https://arxiv.org/abs/2511.08847)**  
  _Thu, 13 Nov 2025 00:00:00 -0500_  
  arXiv:2511.08847v1 Announce Type: new 
Abstract: Alzheimer's disease (AD) is characterized by the progressive spread of pathology across brain networks, yet forecasting this cascade at the individual level remains challenging. We present a personalized graph-based dynamical model that captures the spatiotemporal evolu…

- **[Path Signatures Enable Model-Free Mapping of RNA Modifications](https://arxiv.org/abs/2511.08855)**  
  _Thu, 13 Nov 2025 00:00:00 -0500_  
  arXiv:2511.08855v1 Announce Type: new 
Abstract: Detecting chemical modifications on RNA molecules remains a key challenge in epitranscriptomics. Traditional reverse transcription-based sequencing methods introduce enzyme- and sequence-dependent biases and fragment RNA molecules, confounding the accurate mapping of mo…

- **[Partial domain adaptation enables cross domain cell type annotation between scRNA-seq and snRNA-seq](https://arxiv.org/abs/2511.08996)**  
  _Thu, 13 Nov 2025 00:00:00 -0500_  
  arXiv:2511.08996v1 Announce Type: new 
Abstract: Accurate cell type annotation across datasets is a key challenge in single-cell analysis. snRNA-seq enables profiling of frozen or difficult-to-dissociate tissues, complementing scRNA-seq by capturing fragile or rare cell types. However, cross-annotation between these t…

- **[OMOP ETL Framework for Semi-Structured Health Data](https://arxiv.org/abs/2511.09017)**  
  _Thu, 13 Nov 2025 00:00:00 -0500_  
  arXiv:2511.09017v1 Announce Type: new 
Abstract: Healthcare data are generated in many different formats, which makes it difficult to integrate and reuse across institutions and studies. Standardisation is required to enable consistent large-scale analysis. The OMOP-CDM, developed by the OHDSI community, provides one…

- **[DeepVRegulome: DNABERT-based deep-learning framework for predicting the functional impact of short genomic variants on the human regulome](https://arxiv.org/abs/2511.09026)**  
  _Thu, 13 Nov 2025 00:00:00 -0500_  
  arXiv:2511.09026v1 Announce Type: new 
Abstract: Whole-genome sequencing (WGS) has revealed numerous non-coding short variants whose functional impacts remain poorly understood. Despite recent advances in deep-learning genomic approaches, accurately predicting and prioritizing clinically relevant mutations in gene reg…

- **[Characterizing sleep stages through the complexity-entropy plane in human intracranial data and in a whole-brain model](https://arxiv.org/abs/2511.09243)**  
  _Thu, 13 Nov 2025 00:00:00 -0500_  
  arXiv:2511.09243v1 Announce Type: new 
Abstract: Characterizing the brain dynamics during different cortical states can reveal valuable information about its patterns across various cognitive processes. In particular, studying the differences between awake and sleep stages can shed light on the understanding of brain…

- **[A thermoinformational framework for the description of neuropsychological systems](https://arxiv.org/abs/2511.09506)**  
  _Thu, 13 Nov 2025 00:00:00 -0500_  
  arXiv:2511.09506v1 Announce Type: new 
Abstract: This work presents a statistical thermodynamics-inspired framework that summarizes multichannel EEG and behavior using macroscopic state variables (entropy, internal energy, temperature, Helmholtz free energy) to quantify stability and reconfiguration in neuropsychologi…

- **[Backcasting biodiversity at high spatiotemporal resolution using flexible site-occupancy models for opportunistically sampled citizen science data](https://arxiv.org/abs/2511.08802)**  
  _Thu, 13 Nov 2025 00:00:00 -0500_  
  arXiv:2511.08802v1 Announce Type: cross 
Abstract: For many taxonomic groups, online biodiversity portals used by naturalists and citizen scientists constitute the primary source of distributional information. Over the last decade, site-occupancy models have been advanced as a promising framework to analyse such loose…

- **[DeepDR: an integrated deep-learning model web server for drug repositioning](https://arxiv.org/abs/2511.08921)**  
  _Thu, 13 Nov 2025 00:00:00 -0500_  
  arXiv:2511.08921v1 Announce Type: cross 
Abstract: Background: Identifying new indications for approved drugs is a complex and time-consuming process that requires extensive knowledge of pharmacology, clinical data, and advanced computational methods. Recently, deep learning (DL) methods have shown their capability fo…

- **[Measuring irreversibility in stochastic systems by categorizing single-molecule displacements](https://arxiv.org/abs/2511.09183)**  
  _Thu, 13 Nov 2025 00:00:00 -0500_  
  arXiv:2511.09183v1 Announce Type: cross 
Abstract: Quantifying the irreversibility and dissipation of non-equilibrium processes is crucial to understanding their behavior, assessing their possible capabilities, and characterizing their efficiency. We introduce a physical quantity that quantifies the irreversibility of…

- **[Genuine and spurious bistability in a simple epidemic model with waning immunity](https://arxiv.org/abs/2511.09196)**  
  _Thu, 13 Nov 2025 00:00:00 -0500_  
  arXiv:2511.09196v1 Announce Type: cross 
Abstract: We study an infection-age structured epidemic model in which both the infectivity and the rate of loss of immunity depend on the time-since-infection. The model can be equivalently viewed as a nonlinear renewal equation for the incidence of infection or as a partial d…

- **[Controllable protein design through Feynman-Kac steering](https://arxiv.org/abs/2511.09216)**  
  _Thu, 13 Nov 2025 00:00:00 -0500_  
  arXiv:2511.09216v1 Announce Type: cross 
Abstract: Diffusion-based models have recently enabled the generation of realistic and diverse protein structures, yet they remain limited in their ability to steer outcomes toward specific functional or biochemical objectives, such as binding affinity or sequence composition.…

- **[Multi-step Predictive Coding Leads To Simplicity Bias](https://arxiv.org/abs/2511.09290)**  
  _Thu, 13 Nov 2025 00:00:00 -0500_  
  arXiv:2511.09290v1 Announce Type: cross 
Abstract: Predictive coding is a framework for understanding the formation of low-dimensional internal representations mirroring the environment's latent structure. The conditions under which such representations emerge remain unclear. In this work, we investigate how the predi…

- **[Simulating Mono-and Multi-Protein Phosphorylation within Nanoclusters](https://arxiv.org/abs/2511.09295)**  
  _Thu, 13 Nov 2025 00:00:00 -0500_  
  arXiv:2511.09295v1 Announce Type: cross 
Abstract: Protein nanoclustering is a characteristic feature of their activated state and is essential for forming numerous subcellular structures. The formation of these nanoclusters is highly dependent on a series of post-translational modifications, such as mono-and multi-ph…

- **[MIFA: Metadata, Incentives, Formats, and Accessibility guidelines to improve the reuse of AI datasets for bioimage analysis](https://arxiv.org/abs/2311.10443)**  
  _Thu, 13 Nov 2025 00:00:00 -0500_  
  arXiv:2311.10443v3 Announce Type: replace 
Abstract: Artificial Intelligence methods are powerful tools for biological image analysis and processing. High-quality annotated images are key to training and developing new methods, but access to such data is often hindered by the lack of standards for sharing datasets. We…

- **[Multi-Scale Hybrid Modeling to Predict Cell Culture Process with Metabolic Phase Transitions](https://arxiv.org/abs/2412.03883)**  
  _Thu, 13 Nov 2025 00:00:00 -0500_  
  arXiv:2412.03883v2 Announce Type: replace 
Abstract: To advance understanding of cellular metabolism and reduce batch-to-batch variability in cell culture processes, this study introduces a multi-scale hybrid modeling framework designed to simulate and predict the dynamic behavior of CHO cell cultures undergoing metab…

- **[Proton Flows, Proton Gradients and Subcellular Architecture in Biological Energy Conversion](https://arxiv.org/abs/2503.03913)**  
  _Thu, 13 Nov 2025 00:00:00 -0500_  
  arXiv:2503.03913v3 Announce Type: replace 
Abstract: Hydrogen cations, or protons, provide the medium by which energy is stored and converted in biological systems. Such pre-eminence relies on the interplay between interfacial and bulk chemical transformations, according to mechanisms that are shared by organisms in a…

- **[Learning conformational ensembles of proteins based on backbone geometry](https://arxiv.org/abs/2503.05738)**  
  _Thu, 13 Nov 2025 00:00:00 -0500_  
  arXiv:2503.05738v2 Announce Type: replace 
Abstract: Deep generative models have recently been proposed for sampling protein conformations from the Boltzmann distribution, as an alternative to often prohibitively expensive Molecular Dynamics simulations. However, current state-of-the-art approaches rely on fine-tuning…

- **[Exploiting individual differences to bootstrap communication](https://arxiv.org/abs/2504.05211)**  
  _Thu, 13 Nov 2025 00:00:00 -0500_  
  arXiv:2504.05211v3 Announce Type: replace-cross 
Abstract: Establishing a communication system is hard because the intended meaning of a signal is unknown to its receiver when first produced, and the signaller also has no idea how that signal will be interpreted. Most theoretical accounts of the emergence of communica…

- **[Fractal geometry predicts dynamic differences in structural and functional connectomes](https://arxiv.org/abs/2505.11477)**  
  _Thu, 13 Nov 2025 00:00:00 -0500_  
  arXiv:2505.11477v2 Announce Type: replace-cross 
Abstract: Understanding the intricate architecture of brain networks and its connection to brain function is essential for deciphering the underlying principles of cognition and disease. While traditional graph-theoretical measures have been widely used to characterize…

- **[A Dynamical Cartography of the Epistemic Diffusion of Artificial Intelligence in Neuroscience](https://arxiv.org/abs/2507.01651)**  
  _Thu, 13 Nov 2025 00:00:00 -0500_  
  arXiv:2507.01651v2 Announce Type: replace-cross 
Abstract: Neuroscience and AI have an intertwined history, largely relayed in the literature of both fields. In recent years, due to the engineering orientations of AI research and the monopoly of industry for its large-scale applications, the mutual expansion of neuros…

- **[Simulation-based inference of yeast centromeres](https://arxiv.org/abs/2509.00200)**  
  _Thu, 13 Nov 2025 00:00:00 -0500_  
  arXiv:2509.00200v2 Announce Type: replace-cross 
Abstract: The chromatin folding and the spatial arrangement of chromosomes in the cell play a crucial role in DNA replication and genes expression. An improper chromatin folding could lead to malfunctions and, over time, diseases. For eukaryotes, centromeres are essenti…
